| EVIDENCE
WATCH
A review and assessment of recent
clinical trial data
Head
and neck cancer
STANDARD CISPLATIN/INFUSIONAL 5-FLUOROURACIL
(PF) VS DOCETAXEL (T) PLUS PF (TPF) AS NEOADJUVANT CHEMOTHERAPY
FOR NONRESECTABLE LOCALLY ADVANCED SQUAMOUS CELL CARCINOMA OF
THE HEAD AND NECK (LA-SCCHN): A PHASE III TRIAL OF THE EORTC
HEAD AND NECK CANCER GROUP (EORTC #24971). (ASCO)
CETUXIMAB PROLONGS SURVIVAL IN PATIENTS
WITH LOCOREGIONALLY ADVANCED SQUAMOUS CELL CARCINOMA OF HEAD
AND NECK: A PHASE III STUDY OF HIGH DOSE RADIATION THERAPY
WITH OR WITHOUT CETUXIMAB. (ASCO)
Chronic
lymphocytic leukemia
ZAP-70 PROTEIN TYROSINE KINASE IS AN INDEPENDENT MARKER OF
DISEASE PROGRESSION IN B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA.
(EHA)
| 
